Employees: 27
Size Anbio Biotechnology (NNNN) is a United States Health Care company (Medical Specialties) with a market value of $518M, the 2650th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.60 on 18 Nov 2026.
Performance Over six months the shares fell 88.7%, against -19.1% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 10.2% over the last twelve months (peer median +3.9%); the operating margin is 66.7% (peer median 2.2%).
Short interest Short interest is 0.1% of the free float (30 Oct 2026).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | $9.76M | $8.85M | $7.26M | $24.7M |
| Revenue growth | — | +10% | +22% | -71% | — |
| Gross profit | n/a | $8.51M | $6.37M | $3.63M | $13.2M |
| EBITDA | n/a | $6.51M | $2.16M | $2.13M | $10.7M |
| Net income | n/a | $7.23M | $2.57M | $2.44M | $10.5M |
| Free cash flow | n/a | -$7.61M | $2.25M | $971,240 | $4.72M |
| Capital expenditure | n/a | $0 | $0 | $0 | $0 |
| Total debt | n/a | $0 | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NNNN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.5% | -6.7% | 9th highest of 21 |
| 6-month return | -88.7% | -19.1% | lowest of 21 |
| Distance from 52-week high | -92.0% | -40.9% | lowest of 21 |
| Revenue growth (TTM) | +10.2% | +3.9% | 5th highest of 21 |
| Operating margin | 66.7% | 2.2% | highest of 21 |
| Net debt / EBITDA | -2.1× | -1.2× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | 1.5× | 6.0% | -7.7% |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 3.9× | 0.4% | -13.2% |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 1.6× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | 125.0× | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | 5.4× | 30.8% | -18.6% |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | 6.7× | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | 0.8× | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | 26.5× | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | 1.6× | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 5.3× | 20.1% | +4.2% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 2.6× | 10.2% | +6.5% |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 1.4× | 4.5% | +5.0% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | 5.5× | 15.0% | -19.8% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 2.2× | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 1.3× | -6.5% | -4.3% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 7.0× | 4.3% | +24.4% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | 3.1× | 55.3% | -4.7% |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | 5.9× | n/a | n/a |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 6.1× | 7.1% | +10.0% |